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Single-sample techniqueGene-expression microarrays allow researchers to characterize biological phenomena in a high-throughput
fashion but are subject to technological biases and inevitable variabilities that arise during sample collection
and processing. Normalization techniques aim to correct such biases. Most existing methods require multiple
samples to be processed in aggregate; consequently, each sample's output is inﬂuenced by other samples
processed jointly. However, in personalized-medicine workﬂows, samples may arrive serially, so renormalizing
all samples upon each new arrivalwould be impractical.Wehave developed Single Channel ArrayNormalization
(SCAN), a single-sample technique that models the effects of probe-nucleotide composition on ﬂuorescence
intensity and corrects for such effects, dramatically increasing the signal-to-noise ratiowithin individual samples
while decreasing variation across samples. In various benchmark comparisons, we show that SCAN performs as
well as or better than competing methods yet has no dependence on external reference samples and can be
applied to any single-channel microarray platform.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Gene-expression microarrays enable high-throughput characteriza-
tions of biological phenomena. They are used widely in the investigation
of biological and clinical phenotypes and have begun to be disseminated
in clinical settings [1–3] via “personalized-medicine” workﬂows. For
example, expression proﬁles representing prognostic subclasses of breast
cancer are being used to guide treatment decisions and have been shown
to inﬂuence medical-oncologist treatment recommendations [4]. Devel-
oping such a workﬂow involves two distinct steps: 1) identiﬁcation of
expression proﬁles that reliably characterize subclasses and 2) compar-
ison of new breast-cancer samples against those proﬁles to predict each
sample's subclass. However, a critical preliminary step is to normalize
each microarray sample to adjust for technological biases and non-
biological variabilities that arise during sample collection and processing
and that obfuscate true signal. Traditional normalizationmethods require
groups of samples to be processed jointly—thus each time a new samplearmacology and Toxicology,
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rights reserved.arrived, all samples would need to be renormalized. Clearly, this type
of approach presents serious logistical and reproducibility challenges and
obviates the need for methods that process samples individually. To
address this need, we developed Single Channel Array Normalization
(SCAN), a normalization technique that uses data observed within a
given microarray sample to correct for probe-nucleotide biases and to
produce standardized output values that remain constant irrespective
of any other sample. Furthermore, unlike competing methods, SCAN
requires no ancillary reference samples to perform these corrections
and can be applied to any one-color microarray.
Many normalizationmethods–including the popular RobustMulti-
chip Average (RMA) [5] and its probe-sequence-adjusting counter-
part, GeneChip RMA (GC-RMA) [6]–borrow information from other
samples to estimate probe-level effects and to standardize variances
across arrays. However, with such approaches, output values for any
given array depend on the quantity and quality of other arrays that
are processed jointly (see Fig. 1A). In an attempt to address such
limitations, two normalization techniques capable of processing indi-
vidual samples have gained popularity. The MAS5 algorithm [7], devel-
oped by Affymetrix, uses mismatch probes with single-base differences
to correct for background variation. As such, this method attempts
to minimize probe-level effects by observing such effects in probes
with nearly identical sequences. Despite the relative simplicity of its
algorithmic approach, MAS5 has performed well against multi-array
methods [8]; however, this algorithm can only be applied to platforms
containing mismatch probes, which excludes the newer Affymetrix
Multi-array Single-array
Affymetrix Array Version RMA fRMA MAS5 SCAN
HG-U95Av2 X X X
HG-U133A X X X X
HG-U133B X X X
HG-U133A 2 X X X
HG-U133 Plus 2 X X X X
HT HG-U133A X X X
XXST1.0GeneHG
XXTS0.1ExonHG
A
B
Fig. 1.Multi-array versus single-array normalization. A) With multi-array methods, such as RMA, samples are processed in groups. Thus when new samples have been hybridized–
for example, in personalized-medicine settings–all samples, old and new, may need to be renormalized as a group, which may require reanalysis of the data or recalibration of
biomarkers. Contrarily, with single-array methods, including SCAN, each sample is normalized individually. Thus newly arrived samples remain separate during normalization, and
data values for existing samples do not change. B) Affymetrix offers many different array versions to quantify human gene expression. SCAN can normalize any version. However,
fRMA does not currently support most array versions because an inadequate number and diversity of previously hybridized samples have been made available publicly. And
because MAS5 relies on mismatch probes, it is unable to normalize samples from newer array versions.
338 S.R. Piccolo et al. / Genomics 100 (2012) 337–344Gene ST, Exon ST, and GG-H arrays (see Fig. 1B). Recently, McCall et al.
introduced another single-sample approach, frozen RMA (fRMA) [9],
which borrows information from publicly available arrays of the same
platform. A key prerequisite to applying fRMA is that a reference data-
base be derived from a large set of biologically diverse samples from a
wide variety of studies. For the array platforms currently supported by
fRMA, approximately 6000 “well-annotated” samples (fromwhich 850
were randomly selected) were used to derive each reference database.
However, obtaining such a large and diverse sample set is currently
impossible for many platforms, and this approach requires arbitrary
decisions of which samples to consider and a deliberate effort to con-
struct a reference set for each unique platform.
To overcome these limitations, SCAN estimates the effect of probe-
nucleotide composition on ﬂuorescence intensity through a linear
statistical model and distinguishes between background noise and
biological signal with a mixture-modeling approach. Probe-level values
are standardized against the variance observed for other probes on the
same array that have similar binding-afﬁnity-adjusted intensities. In this
light, our approach is more appropriately deemed a standardization–
rather than themore commonly termed normalization–approach; how-
ever, to be consistent with the current terminology in the ﬁeld, we use
both terms interchangeably here. Because SCAN processes a given array
only using information intrinsic to that array, normalized values are
independent of any other sample that may have been hybridized in
the same batch. Also importantly, to process a large number of arrays,
computer memory must only be adequate to process a single array at
a time, making SCAN a versatile approach that can be used on low-
memory desktop computers or compute nodes, even when existing
methods fail to process the set of arrays simultaneously. However, in the
case where a large number of processors and memory are available,
SCAN can be used to process multiple arrays in parallel.In this study, we demonstrate that SCAN corrects for probe-level
effects associated with GC bias and drastically increases the signal-to-
noise ratio within each array. We show that SCAN compares favorably
against RMA, fRMA, and MAS5 in its ability to detect differences in
expression across a wide spectrum of RNA spike-in concentrations.
Using data from the Connectivity Map (CMAP) [10], we demonstrate
SCAN's methodological advantages in dealing with batch effects [11]
and differences between array versions. Strikingly, we show that
SCAN enables effective concurrent use of independent gene-expression
datasets. In particular, in an analysis of two independent microarray
compendia that proﬁle identical cell lines–Broad-Novartis Cancer Cell
Line Encyclopedia (CCLE) and GSK Cancer Cell Line Genomic Proﬁling
Data–we show that SCAN produces highly consistent values for samples
grown, processed, and hybridized by independent groups at separate
times. Finally, in a pathway-based analysis, we show that SCAN-based
predictions are highly concordant across the data sets which are known
to contain batch effects.
2. Results
2.1. General description of SCAN standardization approach
The most common approaches to normalizing and summarizing
microarray data simultaneously process a series of samples, causing
measurements for each sample to be dependent on other samples
in the group. This approach can lead to signiﬁcant batch effects and
can create discrepant results between datasets that are normalized
separately, thus creating problems for applications in personalized
medicine. Furthermore, processing large datasets may require exces-
sive amounts of physical memory or splitting large datasets in order
to successfully complete the normalization process. SCAN has been
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Fig. 2. Proportion GC content versus probe intensity. A) For an Affymetrix Human Exon
ST 1.0 array (GSE25219), this ﬁgure illustrates the relationship between probe-level GC
content and expression intensities. As GC content increases, raw intensity also tends to
increase. B) After SCAN processing, this bias is removed.
Table 1
Summary of probe-level metrics for SCAN normalization. SCAN was applied to 100
Affymetrix Human Exon 1.0 ST arrays from publicly available data representing spatio-
temporal transcription patterns in the human brain (GSE25219) [26]. This table lists
various probe-level metrics that characterize SCAN's ability to account for variation and
to magnify signal in the data.
Metric Average Minimum Maximum
Proportion of active probes in sample 0.208 0.154 0.263
Proportion of total variation explained by model 0.792 0.757 0.814
Proportion of variation attributed to
background noise
0.439 0.280 0.634
Estimated signal-to-noise ratio before
application of SCAN
1.357 0.578 2.574
Estimated signal-to-noise ratio after SCAN 6.554 2.632 13.13
Percent increase in signal-to-noise ratio after SCAN 482% 412% 538%
339S.R. Piccolo et al. / Genomics 100 (2012) 337–344developed to resolve these limitations, and is highly effective at
standardizing array data to control for background and individual
array signal.
SCAN utilizes a modiﬁcation of the MAT standardization approach
developed for Affymetrix tiling arrays [12]. The MAT method models
expected probe behavior based on the individual probe sequence and
other probes on the array with similar nucleotide composition and
removes effects due to base-pair content and array bias. Kapur et al.
successfully applied the MAT model to Affymetrix Exon ST arrays [13],
but in their approach parameters were estimated using all data from
each array. This assumption is reasonable for tiling arrays where the
number of probes measuring signal is small with respect to the number
of probes measuring background signal, but is not appropriate for RNA-
based expression array experiments due to the high percentage of
probes that measure true signal. Therefore, our novel modeling
procedure is based on a mixture of two Gaussian distributions with
MAT-like models for the means of both distributions—one mixture
component measuring background noise and the other measuring
biological signal (plus background). The component of interest is the
background distribution, which is used by SCAN to standardize the
probe-level data by subtracting out the background mean and then
standardizing the variance based on the estimated variance of other
probes with similar expected background. As illustrated below, this
approach is highly effective at removing GC effects and other probe and
array-speciﬁc variation from each sample individuallywhile leaving the
biological signal intact, thus increasing the signal-to-noise ratio within
the array while reducing technical variation between arrays.
2.2. SCAN corrects for GC bias inherent to one-color arrays
SCAN accounts for GC bias using a reﬁned linear statistical model
that includes effects for the counts of each nucleotide type separately,
the nucleotide count squared, and also the location of each nucleotide
type on the probe. Using publicly available CEL ﬁles downloaded from
Gene Expression Omnibus (GEO) [14], we have tested SCAN on a wide
variety of Affymetrix platforms, including those that are widely used–
including Human Genome U133A, Human Genome U133 Plus 2.0, and
Human Exon 1.0 ST–aswell as those that have been released recently or
that have been less utilized. Uponanalyzing these samples, we observed
a strong GC bias prior to normalization—probes associated with higher
GC content tended to have higher raw-intensity values (see Fig. 2A).
We assessed for GC bias after normalization and observed that SCAN
abrogated this bias (see Fig. 2B). This result illustrates that SCAN can
correct for binding-afﬁnity biases using only data from within a given
sample.
2.3. Overall microarray signal-to-noise explained by SCAN model
A unique advantage of SCAN is that it directly identiﬁes systematic
within-array variation that can be explained as probe effects and
removes this variation from the data. For probes measuring both
signal and noise, this method only removes noise and leaves the
signal intact. When applied to a set of 100 Affymetrix Human Exon
ST 1.0 arrays (GSE25219), SCAN estimated that an average of 79% of
probes are only measuring background noise and exhibit no signal
above background. In these arrays, we estimate that an average of
35% of the total squared variation in the array data is attributable to
background signal. In all, the probe-mixture model accounts for an
average of 79% of the variation in the data, and 44% of this explained
variation is attributable to background noise (probe effects) and thus
removed. Therefore, we estimate the average overall signal-to-noise
ratio to be 1.4 in the raw data; this is improved to 6.5 after removing
probe-speciﬁc noise, resulting in a relative increase of 482% in the
overall signal-to-noise ratio. Table 1 summarizes these results and
gives ranges for these values across all arrays in the dataset we
examined. Therefore these results show that SCAN is highly effectiveat removing background variation and magnifying signal within each
array.2.4. SCAN detects transcription levels with high sensitivity and speciﬁcity
Nextwe assessed SCAN's ability to detect known transcription levels
in theAffymetrix HumanGenomeU133 Latin Square data (http://www.
affymetrix.com/support/technical/sample_data/datasets.affx), which is
designed to support comparisons of analysis methods. This data set
340 S.R. Piccolo et al. / Genomics 100 (2012) 337–344contains 14 distinct concentrations of spiked transcripts, ranging from
0.125 picomolar (pM) to 512 pM, which were hybridized to Affymetrix
U133A microarrays. After normalization and summarization, we sorted
expression levels for the human cell-line probeset groups by pM con-
centration and then averaged the values across all samples. For each
concentration, we generated receiver-operating-characteristic (ROC)
curves to evaluate how well “expressed” transcripts could be differen-
tiated from “non-expressed” transcripts, using that concentration as
a threshold. We then calculated the mean area under the ROC (AUC)
across all thresholds and used this value as a comparison metric.
Identical processing steps were followed for the SCAN, fRMA, RMA, and
MAS5 normalizationmethods. As shown in Supplementary Figs. 1 and 2,
MAS5 and SCAN performed best, attaining mean AUCs of 0.977 and
0.976, respectively. Results for fRMA andRMAwere slightly lower (0.960
and 0.959, respectively). Note that although these differences are only
small in these spike-in data, the differences will be magniﬁed in more
complex analysis scenarios, as illustrated in the examples below. These
results suggest that SCAN is highly effective at detecting relativelyminorNo No
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Fig. 3. SCAN adjusts for sample-level variations in expression intensity arising from platform
valproic acid. In B), SCAN normalized values are shown for the same samples. Before norma
distinct batch of samples proﬁled on a speciﬁc Affymetrix platform). After normalization, vdifferences in abundance, a crucial capability for “real-world” studies
where differences in transcription between conditions may be subtle.
2.5. SCAN adjusts for batch and platform effects
In processing large data sets, differences in personnel, equipment,
and laboratory conditions may lead to non-biological variability in
expression, known as batch effects [11]. When multiple array ver-
sions are used for proﬁling, such effects may be ampliﬁed further.
CMAP contains thousands of microarrays that were used to proﬁle
cancer cell line responses to dosage levels of many drugs. We exam-
ined the subset that was used to proﬁle MCF7 cell lines treated with
valproic acid and observed strong batch effects in the raw data (see
Fig. 3A). However, after SCAN normalization, values fell within a
similar range for each array, irrespective of batch or array type (see
Fig. 3B). RMA also standardized the value ranges within each array
type; however, because RMA can only be applied to samples from
a single platform at a time, substantial differences persisted acrossrmalization
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Fig. 4. Correlation of sample-wise expression levels between CCLE and GSK cell lines.
CCLE and GSK data were processed using each normalization method, and sample-wise
Pearson correlation coefﬁcients were calculated. Across the samples, SCAN values were
more highly correlated than for the other normalization methods, suggesting its ability
to produce consistent output values for analogous samples processed in independent
facilities by different personnel at different times. (Correlation coefﬁcients were sorted
for each normalization method independently before plotting.)
341S.R. Piccolo et al. / Genomics 100 (2012) 337–344samplesmeasured on different platforms; a similar patternwas observed
for MAS5 (see Supplementary Fig. 4).
For an additional comparison, we tested how well valproic acid
response could be estimated across the various concentration levels.
For each normalization method, we generated a gene signature using
cell-line data from Cohen et al. [15] and projected this signature onto
the CMAP samples using BinReg 2.0 [16] with no quantile or shift-
scale normalization that might bias the comparison of methods. As
illustrated in Supplementary Fig. 5, each method produced response
predictions that increase by concentration. However, SCAN produced
predictions that ranged nearly from zero to one, whereas RMA and
MAS5 predictions ranged between 0.4 and 0.8. Accordingly, SCAN
appeared to be more effective at characterizing cellular activity asso-
ciated with valproic acid treatment, thus enabling a clearer distinc-
tion between samples that had been treated at lower versus higher
concentrations.
It is important to note that the fRMA software currently provides
external reference vectors for only one (HG-U133A) of the three array
versions used in CMAP. The other two versions (HT_HG-U133A and
HT_HG-U133_EA), which constitute 89.0% of perturbed samples in
CMAP, are unsupported because an inadequate number and diversity
of reference samples have been deposited in GEO. Thus we did not
include fRMA in the CMAP comparisons. This scenario illustrates an
important methodological advantage of SCAN over fRMA; SCAN uses
only data from a given array for normalization and thus can be applied to
any one-color array version, whereas fRMA requires platform-speciﬁc
ancillary samples thatmay ormay not be available. Additionally, because
fRMA reference vectors are derived from different sets of samples for
each platform, platform-speciﬁc noise may be introduced.2.6. Concordance between two cancer cell-line compendia
Next we assessed whether the various normalization methods
would produce consistent values for identical cell lines that were
prepared and hybridized by different personnel, in different facilities,
and at different times. Such differences may cause non-biological
noise that could confound downstream conclusions. We posited that
an effective normalization procedure would reduce the effects of such
noise. To perform this comparison, we obtained raw ﬁles from the
Cancer Cell Line Encyclopedia (CCLE) (http://www.broadinstitute.
org/ccle) and a corresponding data set generated by GlaxoSmithKline
(GSK) [17]. For both data sets, the Affymetrix HumanGenomeU133 Plus
2.0 platform was used for proﬁling. We identiﬁed samples that had been
proﬁled in both CCLE and GSK (n=222). For the GSK data set, which
contained triplicate hybridizations of each cell line, we selected the ﬁrst
sample that had a GAPDH 3′/5′ ratio greater than 3.0. Next we calculated
themean Pearson correlation coefﬁcient between corresponding samples
in CCLE and GSK. SCAN produced highly consistent values across the data
sets and had overall higher correlation coefﬁcients than the other
methods (see Fig. 4 and Supplementary Fig. 3).
In a follow-on analysis, we estimated RAS pathway activation
within the treated cell lines using a methodology developed by Bild
et al. [18] In this approach, a pathway signature is constructed by
comparing expression levels of human primary mammary epithelial
cell cultures infected with recombinant adenoviruses and control
cells infected with green ﬂuorescent protein. After renormalizing RAS
samples from the Bild et al. study, we derived expression signatures
representing pathway activation and projected those signatures onto
the CCLE and GSK samples using the BinReg 2.0 algorithm. Under
the expectation that normalization methods better at ﬁltering non-
biological artifacts would result in greater consistency between the
two data sets, we calculated Pearson correlation coefﬁcients based on
the predicted probabilities of pathway activation. As illustrated in
Fig. 5, SCAN and fRMA performed substantially better (r=0.870,
0.869) than MAS5 and RMA (r=0.757, 0.323).Taken together, these ﬁndings suggest that SCAN produces stan-
dardized data that account for unavoidable variations that occur in
microarray studies.3. Discussion
Prior capital investments in microarray equipment and enormous
troves of institutional and publicly available data will surely lead to
microarrays' continuance as a prominent research tool for years to
come. In the Gene Expression Omnibus alone, hundreds of thousands
of raw data ﬁles are available for secondary analyses [14]. Optimiza-
tion of microarray normalization procedures remains imperative to
genomic research by enabling more accurate characterizations of
biomedical phenomena and providing insights into the design of
RNA-sequencing projects. In this study, we have described SCAN, a
novel normalization technique capable of processing one microarray
sample at a time. Through analyses of spike-in data and cell-line
experiments, we have demonstrated that SCAN performs similarly or
better than several existing methods, including other single-sample
techniques and the most popular multi-sample method.
Various normalization techniques have been proposed over the
years, but most depend on groups of samples for processing. Although
in some simple cases such an approach may be adequate for standard-
izing values within a given data set, sample aggregation introduces
logistical challenges that may limit their usefulness in settings where
samples accrue over time—for example, in personalized-medicine
workﬂows or meta-analyses that span multiple studies. SCAN takes
advantage of the large amount of raw data produced by a given array
and corrects for binding-afﬁnity biases on a single-sample basis. This
approach provides various methodological advantages, including that
no information is borrowed from external samples. Additionally, SCAN
is robust to differences among microarray platforms because the same
linear model is applied for every platform. Indeed, we observed that
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Fig. 5. Comparison of RAS pathway activation probabilities for CCLE and GSK cell line data. The probability of RAS pathway activation was estimated for individual samples in CCLE
and GSK cell lines. For each normalization method, a pathway signature was derived through a comparison of expression levels in RAS-activated cell cultures and controls. The
signatures were then projected onto the cell line data, and a probability of pathway activation was calculated. For SCAN and fRMA (A and B), probabilities were highly concordant
across the data sets, whereas for RAS and MAS5 (C) and D) the probabilities were less concordant and fell within narrower ranges. Lack of replication between data sets may lead to
markedly different biological conclusions, depending on which data set is examined.
342 S.R. Piccolo et al. / Genomics 100 (2012) 337–344SCAN produced highly concordant (see Supplementary Fig. 6) gene-
summarized values for Human Exon ST 1.0 and HG-U133A arrays from
the same ovarian-cancer sample (TCGA-04-1335) [19], even though
the array platforms differ considerably in design and in the number of
probes that they contain.
Across our analyses, SCAN performed as well as or better than all
other techniques, which suggests its superior utility and consistency
as a gene-expression normalization method. In our analyses, the most
popular [9] multi-arraymethod, RMA, underperformed in relation to the
single-array methods. In particular, RMA faltered in its attempts to
produce congruous expression values for the cancer cell-line data that
had been processed and hybridized at different facilities. Conceivably,
RMA's attempt to standardize across arrays introduces subtle biases that
currently hamper cross-study replicability. In fact, Giorgi et al. demon-
strated that RMA's median-polish summarization step can introduce
between-array correlation artifacts [20]. fRMA attempts to overcome
the limitations of multi-array processing by constructing an external
reference database of probe-level effects. Indeed, across the various
analyses that we performed, fRMA performed better than its multi-
array counterpart. However, fRMA comes with practical limitations that
hamper its broad utility. Researchers who desire to apply this method tosamples from array versions that are currently unsupported by fRMA
must go through an extensive process of constructing and validating a
new reference database for each platform. Importantly, variation in the
reference data can itself affect data quality. The SCAN algorithm, on the
other hand, can be applied to any single-channel array (such as those
manufactured by Affymetrix and Nimblegen) that provides a support
ﬁle matching probe sequences with probe coordinates. In some of our
analyses, MAS5 performed similarly to SCAN; however, it also lacked
consistencywhen applied to the cell-line data. And perhapsmost impor-
tantly, MAS5 can only be applied to older generations of Affymetrix
arrays that contain mismatch probes. Affymetrix has also provided
the probe logarithmic intensity error (PLIER) method (http://media.
affymetrix.com/support/technical/technotes/plier_technote.pdf), which
corrects for GC content and can be applied to older- and newer-
generation arrays. However, PLIER relies upon external samples for its
summarization approach and thus was not evaluated in this study.
By accurately distinguishing between true biological signal and
backgroundnoise, SCANhelps elucidate the cellularmechanisms driven
by complex variations in transcriptional activity. Effectively correcting
for technological biases on a single-sample basis is particularly impor-
tant for microarrays to gain acceptance in the clinic.
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4.1. Model-based adjustment for probe-nucleotide composition
To correct for binding-afﬁnity biases, we developed a linear model
that is a variation on the Model-based Analysis of Tiling arrays (MAT)
method [12], which was designed for Affymetrix tiling arrays. MAT
has been shown to account for as much as 50% of the variation that
results from binding-afﬁnity and cross-hybridization effects in tiling-
array samples [12]. As with MAT, our model contains a nucleotide
indicator for each position on a given 25-mer probe sequence, along
with quadratic terms representing nucleotide counts. However, the
novel contribution of SCAN, whichmakes it appropriate for expression-
array experiments, is the use of amixture of two Gaussian distributions,
one mixture component measuring background noise and the other
measuring signal (plus background). Themain component of interest is
the background distribution, as the other componentwill likely result in
a confounded distribution of true biological signal of interest, cross-
hybridization, etc. More speciﬁcally, letting Pi represent the probe-
intensity value for probe i=1,…, N, we assume that log(Pi)=(1−Δi)
Y1i+Δi Y2iwhere Y1i~N(Xiθ1,σ12) and Y2i~N(Xiθ2,σ22),where Xiθm is the
mth mixture-component MAT model for probe i presented in the
following equation for a givenm:
Ymi ¼ αmniT þ∑
25
j¼1
∑
k∈ A;C;Gf g
βmjkIijk þ ∑
l∈ A;C;G;Tf g
γmln
2
il þ εmi ð1Þ
where αm is the baseline value based on the number of T's in the probe
sequence, nil is the nucleotide l count, βmjk is the effect of each
nucleotide k (except T which is alreadymodeled in αm) at each position
j, Iijk is an indicator function such that Iijk=1 if the nucleotide at position
j is k in probe i, γml is the effect of nucleotide count squared, and εmi is
the probe-speciﬁc error term, assumed to follow a normal distribution.
The probe mixture component indicators, Δi, take on the values either
0 or 1, indicating fromwhichmixture component each probewas drawn.
However, these indicators are not observable and will be estimated in
the mixture-modeling procedure. We formulate the above model based
on a ‘missing data’ approach (where the Δis are the missing data), and
apply the Expectation-Maximization (EM) algorithm to estimate the
model parameters [21]. Speciﬁcally, assuming the previously described
Gaussian mixture for log (Pi) and assuming Δi~Bernoulli (π) where π is
the proportion of non-background probes on the array, we obtain the
complete data likelihood of
L y;Δð Þ∝∏
N
i¼1
1−πð Þf 1 yijθ1ð Þ½ 1−Δi πf 2 yijθ2ð Þ½ Δi ; ð2Þ
where f1(yi∣θ1) and f2(yi∣θ2) are Gaussian densities representing the
distributions of the ‘background’ and ‘background+ signal’ distributions
of probe respectively. Because the complete data log-likelihood is linear
in the missing data (Δis), applying the EM algorithm is straight-forward
in this case. The Expectation Step (E-Step) consists of imputing the
missing data in the complete data log-likelihood Eq. (2) with their ex-
pected values using the most recent estimates of the model parameters
from the previous Maximization Step (M-Step). The M-Step then
consists of maximizing the model parameters given using Eq. (2) and
the most recent imputed missing data from the E-step. The E-Step and
M-Step are then iterated until the model parameters converge to the
Maximum Likelihood Estimates (MLEs). These MLEs are then used to
standardize the data as described below.
The model (for each mixture component) contains 80 parameters,
1 for α, 3×25 for β, and 4 for γ. SCAN estimates these parameters by
ordinary least squares using a subset of probes (n=50,000) on the
array. After the parameters have been estimated, a baseline intensity
is predicted for each probe. After ﬁtting the model, we use the back-
ground mixture component to obtain an estimate for the backgroundexpected intensity for probe i, mi, to remove the probe-speciﬁc
variation. We bin probes into groups of 5000 with similar mi and
normalize the data as follows:
ti ¼
log Pið Þ−mi
si bin
ð3Þ
where mi is the baseline intensity predicted by the model based on
the sequence of probe i, and si bin is the standard deviation of the bin
to which probe i belongs.
The MAT statistical model was previously applied to Affymetrix
exon arrays [13]. However, we have incorporated modiﬁcations that
were not included in their approach. Most importantly, their approach
did not take into account that most of the variation in an expression
experiment is likely due to the true biological signal of interest. The
original MAT approach estimates parameters based on all the variation
in the data (background and signal), whichwill remove some biological
signal from the data and result in reduction of the signal-to-noise ratio.
SCAN's novel introduction of a mixture modeling approach results in
the removal of mostly background while preserving the biological
signal in the data.
4.2. Software
SCAN has been implemented as an open-source software package
that can be downloaded freely from http://jlab.bu.edu/software/scan-
upc. It can be applied to any single-channel platform for any species, so
long as metadata describing the coordinates and sequence of each
probe is available. SCAN outputs probe-level expression values, which
by default are summarized to gene-level values using a trimmed mean.
In this study, the R statistical software [22] and its associated
ROCR package [23] were used for analyzing results and producing
graphics. The implementations of fRMA, RMA, and MAS included in
the affy [24] and frma [9] R/Bioconductor packages were applied with
default parameters.
4.3. Data summarization
Affymetrix offers a variety of microarray platforms that target
various applications. For each platform, Affymetrix provides a tab-
delimited ﬁle that indicates the position and sequence of each probe.
We downloaded these ﬁles from http://www.affymetrix.com and
parsed the relevant information into consistently formatted “probe-
tab” ﬁles. (The probe-sequence information for the recently released
Affymetrix GG-H arrays was downloaded from http://gluegrant1.
stanford.edu/~DIC/GGHarray.) By design, Affymetrix places a variety
of background and control probes on the Affymetrix ST and GG-H
arrays. To avoid overﬁtting the linear model, SCAN ignores these
probes when estimating model parameters but does output normal-
ized expression values for these probes. Unlike previous generations
of Affymetrix microarrays, the ST and GG-H arrays also include a
small proportion of probes that have sequences shorter than 25 base
pairs; because the linear model requires all probes to have the same
length, SCAN ignores these probes.
Upon normalizing a CEL ﬁle, SCAN outputs a tab-delimited text ﬁle
containing three columns. The ﬁrst column lists a unique identiﬁer for
each probe (a concatenation of the probe's X and Y position on the
array). The second column lists the normalized expression value for
each probe. And the third column contains values representing the
probability that each probe is expressed above background noise.
(A companion publication describing the latter is pending.)
To support gene-level summaries, probe values aremapped to genes
using either the mapping ﬁles provided by Affymetrix or custom
mapping ﬁles. By default, we use custommapping ﬁles provided by the
BrainArray resource [25]; if no suchmapping ﬁle is available, we default
to mappings provided by Affymetrix. However, users also have the
344 S.R. Piccolo et al. / Genomics 100 (2012) 337–344option to specify alternative mapping ﬁles that adhere to a simple tab-
delimited format. Currently, each human GeneChip platform listed on
http://www.affymetrix.com is supported.
After probes have been mapped to genes, gene-level values are
calculated using a 10% trimmed mean. If fewer than 3 probes are
associated with a gene, no gene-level value is calculated.
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